RESUMO
Spironolactone, a potassium-sparing diuretic metabolized to canrenone is often used with digoxin to treat various conditions including congestive heart failure. Potassium canrenoate is a similar drug, which is also metabolized to canrenone. Due to reported both positive and negative interference of spironolactone, potassium canrenoate, and their common metabolite canrenone with digoxin immunoassays, we investigated potential interference of these compounds with the new homogenous sequential chemiluminescent assay for digoxin based on the luminescent oxygen channeling technology (LOCI digoxin) for application on the Dimension and Vista platform. When aliquots of a drug-free serum pool were supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone and apparent digoxin values were measured using Dimension Vista LOCI digoxin assay, we observed no detected value except when aliquots were supplemented with very high amounts of potassium canrenoate or canrenone. However, we observed that apparent digoxin concentrations were very low. When aliquots of a serum digoxin pool (prepared by pooling specimens from patients receiving digoxin), were further supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone and serum digoxin concentrations were remeasured using the LOCIdigoxin assay, only statistically significant falsely lower digoxin values (negative interference) were observed in specimens containing very high amounts of canrenone or potassium canrenoate. However, such small bias may not have any clinical significance. We conclude that new Dimension Vista LOCI digoxin assay is virtually free from interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone.
Assuntos
Ácido Canrenoico/química , Canrenona/química , Digoxina/sangue , Imunoensaio/métodos , Espironolactona/química , Ácido Canrenoico/sangue , Canrenona/sangue , Digoxina/química , Humanos , Imunoensaio/normas , Medições Luminescentes/métodos , Medições Luminescentes/normas , Modelos Moleculares , Espironolactona/sangueRESUMO
Spironolactone, which is metabolized to canrenone, is often used in combination with digoxin. Potassium canrenoate is a similar drug that is also metabolized to canrenone. As a result of reported interference of spironolactone, potassium canrenoate, and their common metabolite canrenone with digoxin immunoassays, we investigated potential interference of these compounds with two relatively new digoxin assays for application on ARCHITECT clinical chemistry platforms (cDig, particle-enhanced turbidimetric inhibition immunoassay) and ARCHITECT immunoassay platforms (iDig, chemiluminescent microparticle immunoassay), both from Abbott Diagnostics. When aliquots of drug-free serum pool were supplemented with various amounts of spironolactone, potassium canrenoate, and canrenone, no apparent digoxin concentration was observed using cDig assay on ARCHITECT c4000, c8000, and c16000 or iDig assay on i1000SR and i2000SR analyzers. In addition, we observed no false increase in serum digoxin value when aliquots of a digoxin pool were further supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone. We conclude that both the cDig and iDig assays on the ARCHITECT analyzers are free from interferences by spironolactone, potassium canrenoate, and canrenone.
Assuntos
Antiarrítmicos/sangue , Ácido Canrenoico/sangue , Canrenona/sangue , Química Clínica/métodos , Digoxina/sangue , Imunoensaio/métodos , Espironolactona/sangue , Antiarrítmicos/metabolismo , Ácido Canrenoico/metabolismo , Canrenona/metabolismo , Reações Cruzadas , Digoxina/metabolismo , Antagonistas de Receptores de Mineralocorticoides/sangue , Espironolactona/metabolismoRESUMO
Spironolactone, a potassium sparing diuretic metabolized to canrenone, is often used with digoxin to treat various conditions including congestive heart failure. Potassium canrenoate is a similar drug that is also metabolized to canrenone. Due to reported interference of spironolactone, potassium canrenoate, and their common metabolite canrenone with digoxin immunoassays, we investigated potential interference of these compounds with Dimension Vista Digoxin immunoassay using Flex reagent cartridge. Aliquots of a drug-free serum pool were supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone and apparent digoxin values were measured using Dimension Vista digoxin assay, we observed none-detected value except when aliquots were supplemented with higher amounts of spironolactone or canrenone. Similarly, when aliquots of a serum digoxin pool (prepared by pooling specimens from patients receiving digoxin) where further supplemented with various amounts of spironolactone, potassium canrenoate, or canrenone, we observed moderately falsely elevated digoxin values only in specimens containing higher amounts of spironolactone or canrenone. We conclude that spironolactone and canrenone but not potassium canrenoate may cause modest interference with Dimension Vista digoxin assay but such interferences may not be clinically significant except with very high amounts of canrenone.
Assuntos
Ácido Canrenoico/química , Ácido Canrenoico/farmacologia , Canrenona/sangue , Canrenona/química , Cardiotônicos/farmacologia , Digoxina/sangue , Digoxina/química , Imunoensaio , Antagonistas de Receptores de Mineralocorticoides/sangue , Antagonistas de Receptores de Mineralocorticoides/química , Espironolactona/sangue , Espironolactona/química , Bioensaio , Ácido Canrenoico/sangue , Ácido Canrenoico/imunologia , Canrenona/imunologia , Cardiotônicos/sangue , Química Clínica/métodos , Reações Cruzadas , Digoxina/imunologia , Interações Medicamentosas , Monitoramento de Medicamentos , Humanos , Imunoensaio/métodos , Antagonistas de Receptores de Mineralocorticoides/imunologia , Antagonistas de Receptores de Mineralocorticoides/metabolismo , Concentração Osmolar , Kit de Reagentes para Diagnóstico , Espironolactona/imunologia , Espironolactona/metabolismoRESUMO
Spironolactone and potassium canrenoate (aldosterone antagonist diuretics) are often used with digoxin in clinical practice. It has been well documented in the literature that spironolactone, potassium canrenoate, and their common metabolite canrenone cross-react with several digoxin immunoassays at concentrations expected after therapeutic usage of these drugs and falsely elevate or lower serum digoxin concentrations. Recently, Abbott Laboratories marketed a new Digoxin III immunoassay for application on the AxSYM analyzer. We studied the potential interference of these compounds with this new digoxin assay. The Tina-quant assay was used as the reference method because spironolactone, potassium canrenoate, and canrenone do not interfere with serum digoxin measurement using this assay. Aliquots of drug-free serum were supplemented with therapeutic and above therapeutic concentrations of spironolactone, canrenone, and potassium canrenoate, and apparent digoxin concentrations were measured using the Digoxin III assay and Tina-quant assay. Significant apparent digoxin concentrations were observed when the Digoxin III digoxin assay was used, but no apparent digoxin levels was observed using the Tina-quant assay. When serum pools prepared from patients receiving digoxin were further supplemented with these compounds in concentrations expected in sera of patients receiving these medications, falsely elevated digoxin levels were observed using Digoxin III assay, but no statistically significant change was observed using the Tina-quant assay. We conclude that spironolactone, potassium canrenoate, and their common metabolite canrenone interfere with the serum digoxin measurements using the new Digoxin III assay.
Assuntos
Ácido Canrenoico/sangue , Canrenona/sangue , Digoxina/sangue , Imunoensaio , Espironolactona/sangue , Ácido Canrenoico/metabolismo , Reações Cruzadas , Interações Medicamentosas , Humanos , Antagonistas de Receptores de Mineralocorticoides/sangue , Espironolactona/metabolismoRESUMO
While aldosterone receptor blockers improve survival of patients with congestive heart failure, spironolactone and its derivatives were recently shown to block ether-a-go-go-related gene (HERG) channels and native IKs and IKr currents in guinea pig ventricular myocytes. In this study, we examined in vivo electropharmacological effects of an active derivative of spironolactone, potassium canrenoate, using a halothane-anesthetized canine model. Potassium canrenoate was intravenously administered in three doses of 1, 10, and 100 mg/kg per 10 min with a pause of 20 min between doses (n = 5). The low dose hardly affected any of the cardiovascular parameters. The middle dose, a clinically recommended daily maximum i.v. dose, slightly inhibited the intraventricular conduction. The high dose decreased the heart rate, ventricular contraction and blood pressure, delayed the atrioventricular and intraventricular conduction, and prolonged the ventricular repolarization and refractory period. Increment in the refractoriness by the high dose was greater than that in the repolarization, resulting in the reduction of ventricular electrical vulnerability. This unique electrophysiological profile of potassium canrenoate may in part contribute to the favorable clinical results, whereas caution has to be paid on the cardiohemodynamic actions, particularly for patients with risk of elevated plasma drug concentration.
Assuntos
Ácido Canrenoico/farmacologia , Coração/efeitos dos fármacos , Antagonistas de Receptores de Mineralocorticoides/farmacologia , Potenciais de Ação/efeitos dos fármacos , Anestesia , Animais , Pressão Sanguínea/efeitos dos fármacos , Ácido Canrenoico/sangue , Cães , Eletrocardiografia/efeitos dos fármacos , Feminino , Halotano/farmacologia , Coração/fisiologia , Frequência Cardíaca/efeitos dos fármacos , Masculino , Período Refratário Eletrofisiológico/efeitos dos fármacosRESUMO
Digoxin concentrations measured by three automated immunoassay systems, i.e. OPUS, TDx and IMx assays, were compared in order to evaluate precision and accuracy performance, and data compatibility. Coefficients of variation for all methods in within-run and between-run precision were less than 10% at weighed-in concentrations of 0.545, 1.090 and 2.180 ng/ml. The accuracy relative to the three weighed-in concentrations ranged from 97% to 123% for all methods. One hundred and three plasma samples from 60 patients receiving digoxin were used to evaluate the data compatibility. Digoxin concentrations measured by the three immunoassay systems correlated well with one another. These results suggest that there are few problems when switching between digoxin assay methods, and that IMx and OPUS are more useful than TDx because they do not require sample pretreatment. The digoxin concentrations of the plasma samples from one patient receiving both digoxin and potassium canrenoate were investigated as a case report. The digoxin concentrations measured by TDx and IMx became higher than those measured by OPUS after starting the combination treatment. In another patient suffering from bilirubinaemia, the digoxin concentrations measured by TDx or IMx were higher than those measured by OPUS. These results suggest that OPUS has a higher specificity for measuring the plasma digoxin concentrations compared with TDx or IMx.
Assuntos
Imunoensaio de Fluorescência por Polarização/métodos , Imunoensaio/métodos , Análise de Variância , Antiarrítmicos/sangue , Antiarrítmicos/uso terapêutico , Ácido Canrenoico/sangue , Ácido Canrenoico/uso terapêutico , Digoxina/sangue , Digoxina/uso terapêutico , Humanos , Reprodutibilidade dos TestesRESUMO
Spironolactone and potassium canrenoate (aldosterone antagonist diuretics) are often used with digoxin in clinical practice. It has been well documented in the literature that spironolactone, potassium canrenoate, and their common metabolite canrenone cross-react with the fluorescence polarization immunoassay (FPIA) for digoxin and falsely elevate measured serum digoxin concentrations. Recently a new turbidometric assay for digoxin became commercially available from Bayer Diagnostic for application on the ADVIA 1650 Chemistry analyzer. We studied the potential interference of these compounds in this new digoxin assay. Aliquots of drug-free serum were supplemented with therapeutic and above-therapeutic concentrations of spironolactone, canrenone, and potassium canrenoate, and apparent digoxin concentrations were measured. We observed apparent digoxin concentrations with the FPIA digoxin assay as expected but observed no apparent digoxin levels with the new turbidometric immunoassay. When serum pools prepared from patients receiving digoxin were supplemented with these compounds in concentrations expected in serum in patients receiving these medications, we observed falsely elevated digoxin levels with the FPIA digoxin assay, but no statistically significant change was observed with the new turbidometric assay. We conclude that the new turbidometric assay for digoxin is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
Assuntos
Ácido Canrenoico/sangue , Canrenona/sangue , Cardiotônicos/sangue , Digoxina/sangue , Imunoensaio de Fluorescência por Polarização/métodos , Espironolactona/sangue , Reações Cruzadas , Interações Medicamentosas , HumanosRESUMO
Plasma concentrations and urinary excretion of canrenone (III), canrenoic acid (IV) and canrenoic acid glucuronide (V) were determined by means of high performance liquid chromatography (HPLC) and fluorometry after oral administration of spironolactone (I) and potassium canrenoate (II) to human subjects. Comparison of both assays for III in plasma as well as in urine after administration of I showed marked differences. Plasma concentrations of III were significantly higher after administration of II than I, Cmax and AUC from II being 3--5 times larger than those from I by means of HPLC assay, while the fluorometrically determined values for III in plasma after administration of I and II did not differ as much from each other. On the other hand, in contrast to plasma, the amount of III excreted in urine after administration of I was much larger than that after II, i.e. 3--4 times greater by means of HPLC and over 10 times greater by means of fluorometry. These results strongly suggest that precursors of III are formed which have a higher renal clearance than that for III alone after oral administration of I. Considering the relative biological potency ratio of I and II, it is presumed that their pharmacological activities may relate to the urinary excretion of III. Plasma concentrations of IV were definitely higher after administration of II compared to those after I. Canrenoic acid (IV) was excreted mainly as glucuronide (V) in urine.
Assuntos
Ácido Canrenoico/metabolismo , Pregnadienos/metabolismo , Espironolactona/metabolismo , Adulto , Ácido Canrenoico/sangue , Cromatografia Líquida de Alta Pressão , Glucuronatos/sangue , Humanos , Cinética , Masculino , Pessoa de Meia-Idade , Espectrometria de Fluorescência , Espironolactona/sangue , Espironolactona/urinaRESUMO
There is evidence from in vitro experiments that spironolactone not only antagonises the peripheral effects of aldosterone but also inhibits the production of corticosteroids by the adrenals. However relevant data from clinical studies are contradictory probably because spironolactone action on the kidneys also activates other mechanisms, such as renin secretion and potassium retention, which are potent stimulants of the adrenal cortex and thus tend to compensate for the inhibition. To determine the inhibitory effect of spironolactone on the adrenals in isolation, three groups of nephrectomized dogs were studied. Steroidogenesis was stimulated either by angiotensin II, potassium, or ACTH infusion. Potassium canrenoate was administered i.v. bolus at the beginning of the experiment. All the groups showed a similar marked decrease in plasma renin activity (PRA). Plasma aldosterone and cortisol were stimulated by the appropriate stimulus but their increase was blunted after the canrenoate K administration. The altered response between the subgroups was statistically significant (P less than 0.05). Plasma progesterone increased after the administration of canrenoate K. The response difference between the respective subgroups was again statistically significant (P less than 0.05). Canrenoate K was rapidly eliminated from the systemic circulation. These data indicate that canrenoate K causes a partial inhibition of aldosterone and cortisol stimulated secretion but augments the plasma levels of the precursor progesterone, as would be expected following inhibition of specific steps of corticosteroid biosynthesis.
Assuntos
Corticosteroides/biossíntese , Glândulas Suprarrenais/metabolismo , Ácido Canrenoico/farmacologia , Pregnadienos/farmacologia , Glândulas Suprarrenais/efeitos dos fármacos , Hormônio Adrenocorticotrópico/farmacologia , Aldosterona/sangue , Angiotensina II/farmacologia , Animais , Ácido Canrenoico/sangue , Cães , Hidrocortisona/sangue , Técnicas In Vitro , Cinética , Nefrectomia , Renina/sangueAssuntos
Canrenona/farmacologia , Antagonistas de Receptores de Mineralocorticoides , Pregnadienos/farmacologia , Adulto , Animais , Ácido Canrenoico/sangue , Canrenona/sangue , Cromatografia Líquida de Alta Pressão , Diurese/efeitos dos fármacos , Cães , Fludrocortisona/farmacologia , Humanos , Masculino , Potássio/urina , Sódio/urina , Especificidade da Espécie , Espironolactona/farmacologiaRESUMO
In 5 healthy subjects and in 5 patients with decompensated liver diseases, the concentrations of cortisol, canrenone and canrenoate-K were determined after single doses and after a long-term treatment with spironolactone. The concentrations of the metabolites of spironolactone were determined fluorimetrically, those of cortisol by a highly specific radioimmunoassay with previous chromatographic separation. As a result, non-interaction between spironolactone medication and cortisol metabolism, even at high dose and long-term treatment conditions, was established neither in normal test subjects nor in patients with liver failure.
Assuntos
Hidrocortisona/metabolismo , Espironolactona/uso terapêutico , Ácido Canrenoico/sangue , Canrenona/sangue , Interações Medicamentosas , Humanos , Hidrocortisona/sangue , Hepatopatias/sangue , Hepatopatias/tratamento farmacológico , Espironolactona/metabolismoRESUMO
A method of assessing the qualitative and quantitative activity of competitive aldosterone antagonists in healthy man is described. It requires intravenous infusion of aldosterone (0.5 mg/6 h), iv and oral water loading for six hours and fractionated collection of urine over eight hours. Aldosterone antagonists were administered orally 1.5 h before the start of the infusion (spironolactone 50, 200 or 800 mg) or added to the infused solution (potassium cnarenoate 300, 600 or 1000-1200 mg). The effect was assessed by changes in urinary sodium and potassium excretion and in urinary Na+/K+ ratio. The plasma levels and urinary excretion of canrenone, canrenoate and canrenoate ester glucuronide, respectively, were determined after administration of spironolactone and potassium canrenoate. Between 4-8 h (spironolactone) or 2-8 h (potassium canrenoate) after commencement of the infusion there was linear dose-dependent reversal of the mineralocorticoid-induced sodium retention and/or decrease in the Na+/K+ ratio. The plasma levels and urinary excretion of the metabolites measured were also dose-dependent. The method appears suitable for comparison of the potency of aldosterone antagonists and for defining the time course of drug action within the observation period employed.
Assuntos
Antagonistas de Receptores de Mineralocorticoides/farmacologia , Adulto , Aldosterona/farmacologia , Ácido Canrenoico/sangue , Ácido Canrenoico/farmacologia , Avaliação de Medicamentos/métodos , Feminino , Humanos , Masculino , Potássio/farmacologia , Sódio/urina , Espironolactona/sangue , Espironolactona/farmacologia , Fatores de TempoAssuntos
Ginecomastia/sangue , Hipófise/efeitos dos fármacos , Espermatozoides/fisiologia , Espironolactona/toxicidade , Testículo/efeitos dos fármacos , Adulto , Ácido Canrenoico/sangue , Canrenona/sangue , Estradiol/sangue , Hormônio Foliculoestimulante/sangue , Ginecomastia/induzido quimicamente , Humanos , Hormônio Luteinizante/sangue , Masculino , Hipófise/fisiologia , Motilidade dos Espermatozoides/efeitos dos fármacos , Espermatozoides/efeitos dos fármacos , Testículo/fisiologia , Testosterona/sangueRESUMO
An automated two-phase method for the simultaneous fluorometric determination of the spironolactone metabolites canrenone (II) and canrenoic acid (III) in serum is described. The determination is performed by two dichloroethane extractions of the same serum sample at different pH values. The fluorescence developed in 65% (v/v) sulfuric acid is measured in two separate fluorometers (one each for canrenone and canrenoic acid). Comparable specificity and sensitivity to the manual procedure are obtained, with sensitivity limits of 20 ng of II/ml and of 30 ng of III/ml in serum. This method is applicable to the automated determination of drugs and metabolites in biological material when several extraction steps are involved.
Assuntos
Espironolactona/sangue , Autoanálise/instrumentação , Ácido Canrenoico/sangue , Canrenona/sangue , Humanos , Métodos , Espectrometria de Fluorescência , Fatores de TempoRESUMO
The metabolism and tissue distribution of intravenously administered C14-canrenoate-potassium (CR-K) was studied at various time intervals in 10 dogs. After a rapid decline of total radioactivity immediately after injection, the elimination in plasma occurred in two distinct phases with half-lives of 6.8 and 23.6 h. Canrenoate was rapidly converted to lipid- and water-soluble metabolites which were separated by thin-layer chromatography. Most tissues showed similar concentrations of total radioactivity as plasma. An accumulation of radioactivity per g wet weight was detected in the adrenal glands and fat tissue as well as in the metabolic and excretory organs but not in the heart. Taking into consideration that skeletal muscle, fat tissue and liver constitute about 64% of the body weight, it is obvious that the main part of total radioactivity was present in these tissues. In contrast to plasma, urine and feces, where various metabolites could be analysed, the bulk of radioactivity in tissues is represented by canrenone. Thus, the estimation of the parent compound and its metabolites in plasma, urine and feces does not allow final conclusions about the active substance in various tissues. Within 72 h 47% of the dose was recovered in urine and 49% in feces.
Assuntos
Ácido Canrenoico/metabolismo , Pregnadienos/metabolismo , Animais , Bile/metabolismo , Ácido Canrenoico/sangue , Ácido Canrenoico/urina , Cromatografia em Camada Fina , Cães , Fezes/análise , Cinética , Masculino , Fatores de TempoRESUMO
Plasma and various organ concentrations of canrenone, canrenoate, and total 3H-activity were measured following single doses of 20 mg of 3H-canrenoate/kg iv to rabbits. Organs studied included heart, lungs, brain, kidneys, liver, adrenal glands, and spleen. Canrenoate was shown to be in rapid equilibrium with canrenone. Both were eliminated from plasma and other tissues with a half-life of about 1 hr. Plasma concentrations of both drugs were equal as early as 10 min after intravenous drug administration. Canrenone was concentrated about 10-fold in organ tissues when compared to plasma, while no such preferential uptake was found with canrenoate. Total 3H-activity declined slowly in all tissues with a half-life of approximately 15 hr, indicating extensive metabolism and metabolite retention in the rabbit.
Assuntos
Ácido Canrenoico/metabolismo , Pregnadienos/metabolismo , Animais , Ácido Canrenoico/sangue , Canrenona/metabolismo , Feminino , Coelhos , Fatores de TempoRESUMO
Pharmacokinetics of 3H-4''' -methyldigoxin (md) were studied in three paired experiments with and without pretreatment with spironolactone (7 mg/kg/day for 7 days) and in one additional test person after pretreatment only. The results were compared with controls after oral (n equals 6) and intravenous (n equals 6) administration of md. In addition the biliary excretion of md and its metabolites was investigated in biliary fistula patients with and without pretreatment with spironolactone. After pretreatment of normal persons maximum plasma levels of tritium were approximately 35% lower and they were reached on average 60 min after oral administration as compared with approximately 15 min without pretreatment. Already 12 hrs after oral administration the plasma concentrations, with and without pretreatment, no longer differed and the biological half lives of radioactivity in plasma were equal. With or without pretreatment, the cumulative excretion of tritium in urine and faeces was nearly identical in the paired experiments within 7 days. It was in the range of the controls which eliminated 55.2 +/- 2.8 and 28.6 +/- 5.7% of the dose in urine and faeces, respectively, after oral, and 62.2 +/- 2.1 and 28.9 +/- 5.2%, respectively, after i.v. administration. Accordingly after pretreatment the radioactivity excreted in bile within 48 hrs (14.9% of the dose) did not differ from controls. Examination of the composition of labelled compounds excreted in urine and bile revealed no significant alterations in the metabolic degradation of md under the influence of spironolactone. Thus the profound effects of spironolactone upon pharmacokinetics of md previously observed in rats are without any significance for human conditions.
Assuntos
Digoxina/análogos & derivados , Espironolactona/farmacologia , Administração Oral , Adulto , Bile/metabolismo , Ácido Canrenoico/sangue , Canrenona/sangue , Digoxina/administração & dosagem , Digoxina/metabolismo , Fezes/metabolismo , Feminino , Meia-Vida , Humanos , Injeções Intravenosas , Cinética , Masculino , Pessoa de Meia-Idade , Espironolactona/sangue , TrítioRESUMO
The plasma aldosterone radioimmunoassay developed by Ito et al. was found to be non-specific for aldosterone following administration of the spirolactones, spironolactone and canrenoate-K, in rabbits, dogs and humans. The assay interfering principle was identified as a hydroxylated derivative (M-B) of canrenone, which itself is a metabolite common to both spironolactone and canrenoate-K. The metabolite M-B possessed a high cross-reactivity to the 21-hemisuccinate aldosterone antibody relative to other spirolactones. A modified procedure was developed specific for plasma aldosterone in the presence of M-B. Following single doses of spironolactone and canrenoate-K, aldosterone plasma levels were unchanged in humans and in dogs and decreased in rabbits.